The formation of amphotericin B ion channels in lipid bilayers G Fujii, JE Chang, T Coley, B Steere Biochemistry 36 (16), 4959-4968, 1997 | 191 | 1997 |
Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance D Aschenbrenner, M Quaranta, S Banerjee, N Ilott, J Jansen, B Steere, ... Gut 70 (6), 1023-1036, 2021 | 67 | 2021 |
Characterization of high-order diphtheria toxin oligomers B Steere, D Eisenberg Biochemistry 39 (51), 15901-15909, 2000 | 32 | 2000 |
Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model B Steere, JAR Baker, SD Hall, Y Guo Drug Metabolism and Disposition 43 (6), 870-883, 2015 | 23 | 2015 |
Integrated analysis of global mRNA and protein expression data in HEK293 cells overexpressing PRL-1 CM Dumaual, BA Steere, CD Walls, M Wang, ZY Zhang, SK Randall PLoS One 8 (9), e72977, 2013 | 18 | 2013 |
Characterization of high-order oligomerization and energetics in diphtheria toxin B Steere, D Eisenberg University of California, Los Angeles, 2001 | 14 | 2001 |
Simulation of absorption, metabolism, and bioavailability MB Bolger, B Agoram, R Fraczkiewicz, B Steere Drug bioavailability: estimation of solubility, permeability, absorption and …, 2003 | 12 | 2003 |
Concepts for In Vitro Profiling: Drug Activity, Selectivity and Liability MB BOLGER, R FRACZKIEWICZ, M ENTZEROTH, B STEERE Exploiting Chemical Diversity for Drug Discovery, 336-362, 2006 | 8* | 2006 |
Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a phase 2 study B Steere, J Schmitz, N Powell, R Higgs, K Gottlieb, Y Liu, B Jia, JL Tuttle, ... Clinical and translational gastroenterology 14 (7), e00578, 2023 | 6 | 2023 |
A structure-based model of diphtheria toxin action MW Parker, D Eisenberg, CE Bell, MJ Bennett, RJ Collier, ... Protein Toxin Structure, 25-47, 1996 | 6 | 1996 |
Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23 B Steere, C Beidler, A Martin, S Bright, K Kikly, RJ Benschop Journal of Pharmacology and Experimental Therapeutics 387 (2), 180-187, 2023 | 4 | 2023 |
Dop65 mirikizumab regulates genes involved in anti-tnf resistance and ulcerative colitis disease activity B Steere, J Schmitz, N Powell, R Higgs, K Gottlieb, Y Liu, B Jia, JL Tuttle, ... Journal of Crohn's and Colitis 14 (Supplement_1), S103-S104, 2020 | 4 | 2020 |
Predicting drug absorption by computational methods MB Bolger, TM Gilman, R Fraczkiewicz, B Steere, WS Woltosz Cell Culture Models of Biological Barriers, 387-411, 2002 | 4 | 2002 |
DOP09 mirikizumab-induced transcriptome changes in patient biopsies at week 12 are maintained through week 52 in patients with ulcerative colitis T Johnson, B Steere, P Zhang, Y Zang, R Higgs, K Gottlieb, W Reinisch, ... Journal of Crohn's and Colitis 15 (Supplement_1), S047-S048, 2021 | 3 | 2021 |
OP28 Gene expression (GE) values in a phase 2 trial of mirikizumab in ulcerative colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scores B Steere, K Gottlieb, J Schmitz, R Higgs, B Jia, C Milch, J Tuttle, ... Journal of Crohn's and Colitis 14 (Supplement_1), S025-S026, 2020 | 3* | 2020 |
569 A TRANSCRIPTOME-DEPENDENT PROGNOSTIC MODEL OF RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS TS Johnson, W Reinisch, B Steere, C Milch, N Morris, G D'Haens, ... Gastroenterology 164 (6), S-102, 2023 | | 2023 |
P471 A Transcriptome-dependent Prognostic Model of Response in Patients with Ulcerative Colitis T Johnson, W Reinisch, B Steere, C Milch, C Harris, N Morris, G D'Haens, ... Journal of Crohn's and Colitis 17 (Supplement_1), i600-i600, 2023 | | 2023 |
Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52 T Johnson, B Steere, P Zhang, Y Zang, R Higgs, C Milch, W Reinisch, ... Clinical and translational gastroenterology, 10.14309, 2022 | | 2022 |
Tu1467: MIRIKIZUMAB-INDUCED UPREGULATION OF COLONIC TRANSCRIPTS CORRELATES WITH IMPROVEMENTS IN STOOL FREQUENCY IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY … B Steere, N Powell, R Higgs, YC Wang, C Milch, WJ Sandborn, BE Sands, ... Gastroenterology 162 (7), S-973-S-974, 2022 | | 2022 |
DOP86 Mirikizumab-induced upregulation of colonic transcripts correlates with improvements in stool frequency in a phase 2 study of patients with moderately to severely active … B Steere, N Powell, R Higgs, YC Wang, C Milch, WJ Sandborn, BE Sands, ... Journal of Crohn's and Colitis 16 (Supplement_1), i129-i129, 2022 | | 2022 |